Next Article in Journal
Correction: Franco et al. PCL/Mesoglycan Devices Obtained by Supercritical Foaming and Impregnation. Pharmaceutics 2019, 11, 631
Previous Article in Journal
Design and Development of a Bioink for Fabricating Crosslinked Hydrogel Microneedles via 3D Printing for Transdermal Delivery of Estradiol Nanoparticles
Previous Article in Special Issue
A Universal Structural Grammar in Enzyme Fold for Predicting Drug Target Stability: Deciphering Directional Scaffolding via Multi-Stage Pearson Correlation of Asymmetric Contact Matrices
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 18
Issue 7
10.3390/pharmaceutics18070773
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

RAS Inhibitors: Changing the Paradigm from the Undruggable

by
Federica Campana
1,
Emanuela De Bellis
2,
Floriana Porcaro
3,
Gaetano Di Guida
4,
Luigi Della Gravara
4,
Alberto Servetto
3,
Floriana Morgillo
4,
Federica Papaccio
5,6,*,
Amelia Filippelli
5,6,*,
Carminia Maria Della Corte
4,† and
Valeria Conti
5,6,†
1
Department of Human, Philosophical and Formation Sciences, University of Salerno, 84084 Fisciano, Italy
2
PhD School “Clinical and Translational Oncology (CTO)”, Scuola Superiore Meridionale, University of Naples “Federico II”, 80131 Napoli, Italy
3
Department of Clinical Medicine and Surgery, University of Naples “Federico II”, 80131 Naples, Italy
4
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy
5
Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy
6
Clinical Pharmacology Unit, San Giovanni di Dio e Ruggi d’Aragona University Hospital, 84100 Salerno, Italy
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2026, 18(7), 773; https://doi.org/10.3390/pharmaceutics18070773 (registering DOI)
Submission received: 30 April 2026 / Revised: 9 June 2026 / Accepted: 10 June 2026 / Published: 24 June 2026
(This article belongs to the Special Issue Recent Advances in Inhibitors for Targeted Therapies)
Versions Notes

Abstract

For decades RAS mutations represented a chimera for drug developers, as all efforts put into attempting to pharmacologically inhibit them failed. Finally, in recent years, the advent of the KRAS G12C inhibitors sotorasib and adagrasib pushed the development of several new drugs; therefore, the landscape of RAS inhibitors evolved and now includes several compounds with different mechanisms of action. In this review we provide an updated summary of RAS inhibitor drugs, detailing their mechanism of action, pharmacokinetics and toxicity profile as well as efficacy studies.
Keywords: RAS-inhibitors; RAS mutations; solid tumors RAS-inhibitors; RAS mutations; solid tumors

Share and Cite

MDPI and ACS Style

Campana, F.; De Bellis, E.; Porcaro, F.; Di Guida, G.; Della Gravara, L.; Servetto, A.; Morgillo, F.; Papaccio, F.; Filippelli, A.; Della Corte, C.M.; et al. RAS Inhibitors: Changing the Paradigm from the Undruggable. Pharmaceutics 2026, 18, 773. https://doi.org/10.3390/pharmaceutics18070773

AMA Style

Campana F, De Bellis E, Porcaro F, Di Guida G, Della Gravara L, Servetto A, Morgillo F, Papaccio F, Filippelli A, Della Corte CM, et al. RAS Inhibitors: Changing the Paradigm from the Undruggable. Pharmaceutics. 2026; 18(7):773. https://doi.org/10.3390/pharmaceutics18070773

Chicago/Turabian Style

Campana, Federica, Emanuela De Bellis, Floriana Porcaro, Gaetano Di Guida, Luigi Della Gravara, Alberto Servetto, Floriana Morgillo, Federica Papaccio, Amelia Filippelli, Carminia Maria Della Corte, and et al. 2026. "RAS Inhibitors: Changing the Paradigm from the Undruggable" Pharmaceutics 18, no. 7: 773. https://doi.org/10.3390/pharmaceutics18070773

APA Style

Campana, F., De Bellis, E., Porcaro, F., Di Guida, G., Della Gravara, L., Servetto, A., Morgillo, F., Papaccio, F., Filippelli, A., Della Corte, C. M., & Conti, V. (2026). RAS Inhibitors: Changing the Paradigm from the Undruggable. Pharmaceutics, 18(7), 773. https://doi.org/10.3390/pharmaceutics18070773

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop